COMMUNIQUÉS West-GlobeNewswire

Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
05/07/2024
$10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today [...]
Extendicare Announces Timing of 2024 Second Quarter Results and Conference Call
05/07/2024
MARKHAM, Ontario, July 05, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the second quarter of 2024 after market [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/07/2024
DALLAS, July 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/07/2024
SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
05/07/2024
Dijon, le 5 juillet 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence , publie [...]
Long-time collaborators Botond Roska and José-Alain Sahel win the Wolf Prize 2024 in the field of medicine
05/07/2024
Botond Roska and José-Alain Sahel have been awarded the Wolf Prize in Medicine for their pioneering work on restoring vision to blind patients using optogenetic therapy. The Wolf Prize, considered one of the most [...]
FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
05/07/2024
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness Designed to simplify administration, Vabysmo PFS provides retina [...]
Medsenic, subsidiary of BioSenic SA, extends key patent to the United States
05/07/2024
PRESS RELEASE – PRIVILEGED INFORMATION The developed Medsenic’s composition-of-matter patent family does cover the therapeutic use of arsenic salts and metal ions through various routes of administration. Medsenic’s [...]
Medsenic, filiale de BioSenic SA, étend un brevet clé aux États-Unis
05/07/2024
COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE Une famille de brevets récents en cours de développement par Medsenic couvre l'utilisation thérapeutique de sels d'arsenic et d’ions métalliques par diverses voies d' [...]
Major shareholder announcement – BlackRock, Inc.
04/07/2024
4 July 2024 Major shareholder announcement – BlackRock, Inc. ANNOUNCEMENT NO. 271 Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock [...]
KFSH&RC Achieves Remarkable 98% Survival Rate in 400 Robotic Cardiac Surgeries
04/07/2024
RIYADH, Saudi Arabia, July 04, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was [...]
Declaration of shares and voting rights - Valneva SE - June 30, 2024
04/07/2024
VALNEVA Declaration of shares and voting rights June 30, 2024 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]
Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024
04/07/2024
VALNEVA Déclaration d’actions et de droits de vote 30 juin 2024 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 rue [...]
SAFE - Période d’observation prolongée en vue de la présentation du projet de redressement
04/07/2024
POINT SUR LA PROCEDURE DE REDRESSEMENT JUDICIAIRE Période d’observation prolongée en vue de la présentation du projet de redressement Fleurieux-sur-l’Arbresle - France - le 4 juillet 2024 à 18h . Safe SA (FR001400F1V2 [...]
Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024
04/07/2024
Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024. Leuven, BELGIUM - 4 July 2024 – 6:00 PM CET , Oxurion NV (Euronext Brussels: OXUR), a [...]
Grant of Warrants
04/07/2024
4 July 2024 Announcement no. 17 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, July 4, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, [...]
Rafarma pharmaceutical updates: registration of Rafarma microspheres in South Korea
04/07/2024
Sheridan, Wyoming, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce its participation in the scientific conference on radioembolization using [...]
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
04/07/2024
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX ® (etranacogene [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer
04/07/2024
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and overall survival at first interim analysis The combination of [...]

Pages